- Eli Lilly expects FDA decision on Alzheimer’s treatment donanemab by the end of the year CNBC
- US drugmaker: Alzheimer’s development can be slowed down | DW News DW News
- Drug donanemab seen as turning point in dementia fight BBC
- Pharmalittle: Data confirm benefits and risks of Lilly Alzheimer’s drug; Medicare aims to pay hospitals to stockpile essential drugs STAT
- Eli Lilly CEO: Alzheimer’s drug trial shows slowed disease progression by 40-60% in early patients CNBC Television
- View Full Coverage on Google News
Source link